Target-controlled infusion (TCI) is based on pharmacokinetic models designed to achieve a desired drug level in the blood. TCI’s predictive accuracy of plasma propofol levels at the end of surgery with major blood loss has not been well established. This prospective observational study included adult patients (BMI 20–35 kg/m2) undergoing surgery with expected blood loss ≥ 1500 mL. The study was conducted with the Schnider TCI propofol model (Alaris PK Infusion Pump, CareFusion, Switzerland). Propofol levels were assessed in steady-state at the end of anaesthesia induction (Tinitial) and before the end of surgery (Tfinal). Predicted propofol levels (CTCI) were compared to measured levels (Cblood). Twenty-one patients were included. The median estimated blood loss was 1600 mL (IQR 1000–2300), and the median fluid balance at Tfinal was + 3200 mL (IQR 2320–4715). Heart rate, mean arterial blood pressure, and blood lactate did not differ significantly between Tinitial and Tfinal. The median bispectral index (0–100) was 50 (IQR 42–54) and 49 (IQR 42–56) at the two respective time points. At Tinitial, median CTCI was 2.2 µmol/L (IQR 2–2.45) and Cblood was 2.0 µmol/L (bias 0.3 µmol/L, limits of agreement − 1.1 to 1.3, p = 0.33). CTCI and Cblood at Tfinal were 2.0 µmol/L (IQR 1.6–2.2) and 1 µmol/L (IQR 0.8–1.4), respectively (bias 0.6 µmol/L, limits of agreement − 0.89 to 1.4, p < 0.0001). Propofol TCI allows clinically unproblematic conduct of general anaesthesia. In cases of major blood loss, the probability of propofol TCI overestimating plasma levels increases.
Trial registration German Clinical Trials Register (DRKS; DRKS00009312).
Propofol administration Target controlled infusion Automated drug delivery devices
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Struys MM, De Smet T, Glen JI, et al. The history of target-controlled infusion. Anesth Analg. 2016;122:56–69.CrossRefGoogle Scholar
Absalom AR, Mani V, De Smet T, et al. Pharmacokinetic models for propofol–defining and illuminating the devil in the detail. Br J Anaesthesia. 2009;103:26–37.CrossRefGoogle Scholar
Cowley NJ, Hutton P, Clutton-Brock TH. Assessment of the performance of the Marsh model in effect site mode for target controlled infusion of propofol during the maintenance phase of general anaesthesia in an unselected population of neurosurgical patients. Eur J Anaesth. 2013;30:627–32.CrossRefGoogle Scholar
Struys MM, De Smet T, Depoorter B, et al. Comparison of plasma compartment versus two methods for effect compartment-controlled target-controlled infusion for propofol. Anesthesiology. 2000;92:399–406.CrossRefGoogle Scholar
Swinhoe CF, Peacock JE, Glen JB, et al. Evaluation of the predictive performance of a ‘Diprifusor’ TCI system. Anaesthesia. 1998;53(Suppl 1):61–7.CrossRefGoogle Scholar
Cortinez LI, De La Fuente N, Eleveld DJ, et al. Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. Anesth Analg. 2014;119:302–10.CrossRefGoogle Scholar
Sepulveda P, Cortinez LI, Saez C, et al. Performance evaluation of paediatric propofol pharmacokinetic models in healthy young children. Br J Anaesth. 2011;107:593–600.CrossRefGoogle Scholar
Cortegiani A, Pavan A, Azzeri F, et al. Precision and bias of target-controlled prolonged propofol infusion for general anesthesia and sedation in neurosurgical patients. J Clin Pharmacol. 2018;58:606–12.CrossRefGoogle Scholar
Wietasch JK, Scholz M, Zinserling J, et al. The performance of a target-controlled infusion of propofol in combination with remifentanil: a clinical investigation with two propofol formulations. Anesth Analg. 2006;102:430–7.CrossRefGoogle Scholar
Glen JB. The development of ‘Diprifusor’: a TCI system for propofol. Anaesth. 1998;53(Suppl 1):13–21.CrossRefGoogle Scholar
Schnider TW, Minto CF, Struys MM, et al. The safety of target-controlled infusions. Anesth Analg. 2016;122:79–85.CrossRefGoogle Scholar
Bolkenius D, Dumps C, Halbeck E. Drugs for intravenous induction of anesthesia: propofol. Anaesthesist. 2018;67:147–62.CrossRefGoogle Scholar
Glen JB, Servin F. Evaluation of the predictive performance of four pharmacokinetic models for propofol. Br J Anaesth. 2009;102:626–32.CrossRefGoogle Scholar
Sahinovic MM, Eleveld DJ, Miyabe-Nishiwaki T, et al. Pharmacokinetics and pharmacodynamics of propofol: changes in patients with frontal brain tumours. Br J Anaesth. 2017;118:901–9.CrossRefGoogle Scholar
Frei FJ, Zbinden AM, Thomson DA, et al. Is the end-tidal partial pressure of isoflurane a good predictor of its arterial partial pressure? Br J Anaesth. 1991;66:331–9.CrossRefGoogle Scholar
Struys MM, Sahinovic MM, Lichtenbelt BJ, et al. Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts. Br J Anaesth. 2011;107:38–47.CrossRefGoogle Scholar
Nimmo AF, Absalom AR, Bagshaw O, et al. Guidelines for the safe practice of total intravenous anaesthesia (TIVA). Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia. Anaesthesia. 2018. https://doi.org/10.1111/anae.14428.Google Scholar